Search Within
Applied Filters:
Keyword:'O2881'
Showing 1-26 of 26 results for "

O2881

" within Papers
Gary G Kay et al.
Clinical drug investigation, 32(10), 707-714 (2012-08-23)
Oxybutynin is a common antimuscarinic therapy for overactive bladder. Transdermally administered oxybutynin chloride topical gel 10% (OTG) has a low propensity for anticholinergic adverse effects and possibly also a low risk of cognitive impairment. A randomized, double-blind, placebo- and active-controlled...
Lorne E Aaron et al.
Current medical research and opinion, 28(8), 1369-1379 (2012-07-10)
Evaluate patient and physician satisfaction with a novel formulation of a once-daily controlled-release (CR) oxybutynin (Uromax*) 15-mg tablet as both the initial and maintenance dose in elderly and non-elderly patients with overactive bladder (OAB). Patients not on anticholinergic treatment for...
Adding to the evidence base: application drying time for oxybutynin chloride topical gel.
Cynthia M Sublett
Urologic nursing, 32(5), 270-271 (2013-03-12)
Lower urinary tract symptoms revisited.
N I Osman et al.
International journal of clinical practice, 66(6), 527-529 (2012-05-23)
Hulya Dede et al.
Archives of gynecology and obstetrics, 287(3), 511-518 (2012-10-23)
The aim of this study is to evaluate the efficacy and the tolerability of three classic antimuscarinic drugs used in the treatment of over active bladder syndrome using clinical data and quality of life tests, and to evaluate the parameters...
Umberto Leone Roberti Maggiore et al.
Expert opinion on drug metabolism & toxicology, 8(11), 1387-1408 (2012-08-09)
Antimuscarinics (AMs) are the mainstay of pharmacological treatment of overactive bladder (OAB), a symptom complex defined by the presence of urinary urgency, usually associated with frequency and nocturia, with or without urgency urinary incontinence. The AMs used to treat OAB...
K-S Lee et al.
International journal of clinical practice, 66(7), 663-670 (2012-06-16)
Standardised traditional outcome measures may fail to address factors that are important to patients and address irrelevant factors. Aim of this study was to assess patient-reported goals and goal achievement (GA) in the antimuscarinic treatment for overactive bladder (OAB) patients....
Toshiki Hatanaka et al.
Naunyn-Schmiedeberg's archives of pharmacology, 386(1), 71-78 (2012-12-12)
Mirabegron, a selective β(3)-adrenoceptor agonist, facilitates urine storage function by exerting a relaxing effect on bladder smooth muscle. Here, we investigated the effect of mirabegron on bladder function during the storage phase. We assessed the effect of mirabegron on the...
Alex Gomelsky et al.
Expert opinion on pharmacotherapy, 13(9), 1337-1343 (2012-05-23)
Overactive bladder (OAB) is a common condition that has a profound impact on an individual's overall health and quality of life. Muscarinic receptor antagonists are the mainstay of oral pharmacotherapy for OAB. While all of the medications in this class...
C Try et al.
Revue medicale de Liege, 67(10), 520-526 (2012-11-22)
Oxybutynin is being increasingly being prescribed in the treatment of hyperhidrosis but currently, there is no precise dosage for this treatment. Nine patients were treated for primary hyperhidrosis resistant to conventional therapies with oxybutynin between January to May 2010. The...
Michael H Johnson et al.
The Journal of urology, 189(4), 1268-1274 (2012-11-06)
Intravesical bacillus Calmette-Guérin is used to decrease recurrence rates of nonmuscle invasive urothelial carcinoma. Irritative urinary symptoms are a common side effect of treatment and frequently limit treatment tolerance. While anticholinergic medications may be used for symptom prophylaxis, to our...
Nicholas A Williams et al.
Journal of pharmaceutical sciences, 104(7), 2233-2240 (2015-05-20)
Intravesical oxybutynin is highly effective in the treatment of overactive bladder. Traditionally the mechanism of action was explained by antagonism of muscarinic receptors located in the detrusor, however evidence now suggests antimuscarinics may elicit their effect by modifying afferent pathways...
Jessica T Casey et al.
The Journal of urology, 188(4 Suppl), 1516-1520 (2012-08-23)
Abnormal bladder function following posterior urethral valve ablation can lead to deleterious effects on renal function and urinary continence. We performed a pilot study to determine if bladder dysfunction could be ameliorated by the early administration of oxybutynin. We enrolled...
V Schuler et al.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 19(10), 947-951 (2012-07-25)
A broad spectrum of synthetic agents is available for the treatment of overactive bladder. Anti-cholinergic drugs show a poor compliance due to side effects. There is an increasing use of plant extracts in medicine. We have therefore investigated the inhibitory...
A D Asimakopoulos et al.
Urologia internationalis, 89(3), 259-269 (2012-07-11)
To provide an overview on the efficacy, tolerability, safety and health-related quality of life (HRQoL) of drugs with a mixed action used in the treatment of overactive bladder (OAB). MEDLINE database and abstract books of the major conferences were searched...
Tatyana Shamliyan et al.
Annals of internal medicine, 156(12), 861-874 (2012-06-20)
Urinary incontinence (UI) in women adversely affects quality of life. To conduct a systematic literature review of drugs for urgency UI in women. MEDLINE, the Cochrane Central Register of Controlled Trials, SCIRUS, and Google Scholar were searched for articles published...
Got to go! Resolving day and night time enuresis in younger children.
Eileen Jacques
The journal of family health care, 22(2), 26-26 (2012-06-13)
Naoki Aizawa et al.
European urology, 62(6), 1165-1173 (2012-09-18)
Mirabegron is the first β3-adrenoceptor agonist that is clinically effective for overactive bladder. The effects of mirabegron on primary bladder mechanosensitive single-unit afferent activities (SAAs) and bladder microcontractions were evaluated and compared with the effects of oxybutynin. Female Sprague-Dawley rats...
Editorial comment.
Aseem R Shukla
The Journal of urology, 188(4 Suppl), 1520-1520 (2012-08-23)
H Y Chin et al.
Clinical and experimental obstetrics & gynecology, 39(2), 171-174 (2012-08-22)
To evaluate the efficacy of baclofen in combination with antimuscarinics to treat women with an overactive bladder (OAB) with abnormal voiding patterns. An action research and chart review was conducted in 245 OAB women. Women were prescribed tolterodine or oxybutynin...
Daniele Zama et al.
Pediatric transplantation, 17(1), 86-91 (2012-12-13)
HC is a possible cause of morbidity and extended hospitalization after HSCT. Recent studies have reported the efficiency of HOT in adult patients who underwent allogeneic HSCT, but data in children are scarce. We report our single center experience with...
Diane K Newman et al.
Urologic nursing, 32(5), 265-269 (2013-03-12)
This study determined the median drying time for oxybutynin chloride topical gel (OTG) approved for treatment of overactive bladder was 3.1 minutes, Most participants reported positive perceptions of OTG attributes.
Theodore M Johnson et al.
BJU international, 112(1), 100-108 (2013-03-02)
WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Nocturia is a common and bothersome lower urinary tract symptom, particularly in men. Many single drug therapies have limited benefit. For men who have persistent nocturia despite alpha-blocker therapy...
R Cremer
Der Urologe. Ausg. A, 51(7), 991-995 (2012-06-15)
Paraplegic spina bifida patients often suffer from disturbed sweat secretion in the paretic regions. A diminished sweat production of caudal parts of the body is compensated by an increased secretion of sweat in parts cranial to the lesion to maintain...
A review of anticholinergic medications for overactive bladder symptoms.
Rhea Faye Felicilda-Reynaldo
Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses, 22(2), 119-123 (2013-06-28)
P Tauzin-Fin et al.
Annales francaises d'anesthesie et de reanimation, 31(7-8), 605-608 (2012-07-04)
Catheter-related bladder discomfort (CRBD) is an unrecognized clinical event. Symptoms of CRBD secondary to an indwelling urinary catheter mimic those of an overactive bladder, i.e. urinary frequency and urgency with or without urge incontinence. Stimulation of muscarinic receptors located in...
Page 1 of 1
Page 1 of 1